Available Structures
54 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Atomic structure and conformational variability of the HER2-Trastuzumab-Pertuzumab complex |
Heteromer | 100 | 2×NAG; 3×NAG; | |||
| Atomic structure and conformational variability of the HER2-Trastuzumab-Pertuzumab complex |
Heteromer | 100 | 2×NAG; 3×NAG; | |||
| Cryo-EM structure of Her2 extracellular domain-Trastuzumab Fab-Pertuzumab Fab complex |
Heteromer P01834; P0DOX5; Q6GMX6; | 100.0 | 1×NAG; 5×NAG; | |||
| Structure of Zanidatamab bound to HER2 |
Heteromer | 100.0 | ||||
| Crystallographic trimer of HER2 extracellular regions in complex with tryptophan-rich antibody frag… |
Heteromer | 100.0 | 3×NAG; 3×NAG; 3×CL; 48×SO4; | |||
| HuA21-scFv in complex with the extracellular domain(ECD) of HER2 |
Heteromer | 100 | 1×NAG; 1×BMA; | |||
| Crystal structure of extracellular domain of human HER2 complexed with Herceptin Fab |
Heteromer | 100.0 | 2×NAG; 1×SO4; | |||
| Structure of Trastuzumab Fab mutant in complex with Her2 extracellular domain |
Heteromer P0DOX5; Q7Z3Y4; | 100.0 | 1×NAG; | |||
| Dual specific bH1 Fab in complex with the extracellular domain of HER2/ErbB-2 |
Heteromer | 100.0 | 2×NAG; 1×MES; | |||
| Structure of the HER2/HER3/NRG1b Heterodimer Extracellular Domain |
Heteromer P21860; Q02297; | 100.0 | 1×NAG; 2×NAG; 5×NAG; | |||
| Structure of the HER2 S310F/HER3/NRG1b Heterodimer Extracellular Domain |
Heteromer P21860; Q02297; | 99.83 | 2×NAG; 1×NAG; 5×NAG; | |||
| Structure of the HER2/HER4/NRG1b Heterodimer Extracellular Domain |
Heteromer Q02297; Q15303; | 100.0 | 2×NAG; 1×NAG; 5×NAG; 2×NAG; 3×NAG; | |||
| Structure of the HER2/HER4/BTC Heterodimer Extracellular Domain |
Heteromer P35070; Q15303; | 100.0 | 2×NAG; 1×NAG; 5×NAG; 2×NAG; 3×NAG; | |||
| Structure of the HER2/HER3/NRG1b Heterodimer Extracellular Domain bound to Trastuzumab Fab |
Heteromer P21860; Q02297; | 99.83 | 2×NAG; 1×NAG; 5×NAG; | |||
| HER2 extracelluar region with affinity matured 3-helix affibody ZHER2:342 |
Heteromer P38507; | 100.0 | 1×NAG; 2×NAG; | |||
| Crystal structure of extracellular domain of HER2 in complex with Fcab STAB19 |
Heteromer P01857; | 100.0 | 2×NAG; 2×NAG; 2×GOL; 4×NAG; | |||
| The EGF-bound EGFR/HER2 ectodomain complex |
Heteromer P00533; P01133; | 100.0 | 1×NAG; 1×NAG; 2×NAG; | |||
| The EREG-bound EGFR/HER2 ectodomain complex |
Heteromer O14944; P00533; | 100.0 | 1×NAG; 1×NAG; 2×NAG; | |||
| 39S Fab bound to HER2 ecd |
Heteromer | 100.0 | 2×NAG; 1×NAG; | |||
| Crystal structure of extracellular domain of HER2 in complex with Fcab H10-03-6 |
Heteromer P01857; | 100.0 | ||||
| Crystal structure of a HER2-Nb complex |
Heteromer | 100.0 | 1×NAG; 1×NAG; 2×GOL; | |||
| Molecular Architecture of the ErbB2 Extracellular Domain Homodimer |
Heteromer | 100.0 | 1×NAG; | |||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex |
Heteromer Q7Z3Y4; | 100.0 | 2×NAG; 1×NAG; | |||
| Structure of HER2 with an Fab |
Heteromer | 100.0 | ||||
| HER2 in complex with Fab MF3958 |
Heteromer | 100.0 | 1×NAG; 1×NAG; 1×NAG; | |||
| HER2 S310F in complex with TL1 Fab |
Heteromer | 99.6 | 1×NAG; | |||
| NM-02 in complex with HER2-ECD |
Heteromer | 100.0 | 1×NAG; 1×NAG; | |||
| Crystal structure of anti-HER2 antibody H2Mab-119 in complex with HER2 domain I |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of the single-chain Fv (scFv) fragment of an anti-ErbB2 antibody chA21 in complex… |
Heteromer | 100 | ||||
| Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding t… |
Heteromer | 99.41 | ||||
| Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding t… |
Heteromer | 98.8 | ||||
| Crystal structure of HER2 Domain IV and Rb-H2 |
Heteromer | 100 | 1×NAG; | |||
| Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding t… |
Heteromer | 98.59 | ||||
| Heterodimeric association of Transmembrane domains of ErbB1 and ErbB2 receptors Enabling Kinase Act… |
Heteromer P00533; | 100 | ||||
| Solution structure of the human Grb7-SH2 domain in complex with a 10 amino acid peptide pY1139 |
Heteromer Q14451; | 100 | ||||
| Water refined solution structure of the human Grb7-SH2 domain in complex with the 10 amino acid pep… |
Heteromer Q14451; | 100 | ||||
| The Structure of ERBIN PDZ domain bound to the Carboxy-terminal tail of the ErbB2 Receptor |
Heteromer Q96RT1; | 100 | ||||
| POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTE… |
Heteromer P04439; P61769; | 100 | ||||
| Crystal structure of cancer-specific anti-HER2 antibody H2Mab-214 in complex with epitope peptide |
Heteromer | 100 | ||||
| PTPN18 in complex with HER2-pY1248 phosphor-peptides |
Heteromer Q99952; | 100 | ||||
| Phospholipase C gamma-1 C-terminal SH2 domain bound to a phosphopeptide derived from the receptor t… |
Heteromer P08487; | 100 | ||||
| Structural basis of PTPN18 fingerprint on distinct HER2 tyrosine phosphorylation sites |
Heteromer Q99952; | 100 | ||||
| The Structure of ERBIN PDZ domain bound to the Carboxy-terminal tail of the ErbB2 Receptor |
Heteromer Q96RT1; | 100 | ||||
| Homodimeric structure of HER2 S310F extracellular region | homo-2-mer | 99.8 | 2×NAG; | |||
| Spatial structure of HER2/ErbB2 dimeric transmembrane domain in the presence of cytoplasmic juxtame… | homo-2-mer | 100 | ||||
| NMR spatial structure of HER2 TM domain dimer in DPC micelles. | homo-2-mer | 100 | ||||
| ErbB2 transmembrane segment dimer spatial structure | homo-2-mer | 100 | ||||
| Crystal structure of ErbB2 domains 1-3 | monomer | 99.6 | 1×NAG; 2×NAG; | |||
| crystal structure of the receptor tyrosine kinase Human HER2 (ERBB2) YVMA mutant kinase domain in c… | monomer | 100.0 | 1×W9N; 1×PEG; 1×CL; | |||
| HER2 Kinase Domain Complexed with TAK-285 | monomer | 100.0 | 1×03P; | |||
| HER2 in complex with JBJ-08-178-01 | monomer | 100.0 | 1×VOY; | |||
| Crystal Structure of the Kinase domain of Human HER2 (erbB2). | monomer | 98.95 | 1×03Q; | |||
| Crystal structure of kinase domain of HER2 Exon 20 insertion mutant in complex with tucatinib | monomer | 98.95 | 1×A1AAC; 6×EDO; 1×CL; 1×PEG; | |||
| HER2 IN COMPLEX WITH A COVALENT INHIBITOR | monomer | 99.27 | 1×70I; | |||
3 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7mn5.1.C | monomer | 0.79 | 99.90 | |||
| 3bbt.1.A | monomer | 0.69 | 1×FMM; | 72.90 | ||
| 7syd.1.C | monomer | 0.68 | 53.11 | |||
10 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 3pp0.2.A | monomer | 0.75 | 1×03Q; | 98.18 | ||
| Isoform 2 | 7mn8.1.C | monomer | 0.62 | 99.76 | |||
| Isoform 3 | 4riy.2.B | monomer | 0.77 | 1×ADP; | 77.94 | ||
| Isoform 4 | 7mn5.1.C | monomer | 0.79 | 99.31 | |||
| Isoform 4 | 3bbt.1.A | monomer | 0.69 | 1×FMM; | 72.81 | ||
| Isoform 4 | 7syd.1.C | monomer | 0.68 | 52.92 | |||
| Isoform 5 | 7mn5.1.C | monomer | 0.79 | 99.90 | |||
| Isoform 5 | 3bbt.1.A | monomer | 0.69 | 1×FMM; | 72.90 | ||
| Isoform 5 | 7syd.1.C | monomer | 0.68 | 53.13 | |||
| Isoform 6 | 7mn5.1.C | monomer | 0.81 | 94.18 | |||